NeoGenomics Earnings Call Highlights NGS-Led Growth

NeoGenomics Inc. ((NEO)) has held its Q1 earnings call. Read on for the main highlights of the call.

NeoGenomics Inc. used its latest earnings call to underscore a solid growth story, with management striking a confident but measured tone. Double‑digit revenue gains, accelerating next‑generation sequencing demand, and improving profitability framed the narrative, while leaders acknowledged margin pressure, nonclinical weakness, and future refinancing needs as manageable headwinds rather than red flags.

Top-Line Revenue Growth Beats Expectations

NeoGenomics reported total Q1 revenue of $186.7 million, up 11% year over year and above guidance, signaling healthy demand across its core franchise. Clinical revenue did the heavy lifting at $171.2 million, climbing 14% and confirming that the company’s primary testing business remains the key engine of growth.

NGS Emerges as the Primary Growth Engine

Next‑generation sequencing continued to outpace the broader business, with NGS revenue up 26% year over year on 16% volume growth and higher pricing. NGS now represents roughly one‑third of clinical revenue and is scaling three to four times faster than the core clinical portfolio, making sustained adoption critical to NeoGenomics’ long‑term story.

Profitability Edges Higher Despite Headwinds

Adjusted EBITDA reached $9 million in the quarter, a 27% year‑over‑year increase that highlights improving operating leverage as volumes scale. The adjusted EBITDA margin expanded by about 60 basis points, showing that NeoGenomics can grow and invest while gradually lifting profitability even in a choppy cost environment.

Pricing and Volume Show Broad-Based Momentum

Average unit price rose 8% year over year while volumes increased 6%, underscoring both favorable mix and resilient demand from clinicians. Same‑store revenue was $167.9 million, up 12% with 3% volume growth and 9% AUP expansion, suggesting that underlying pricing power and product mix are trending in the right direction.

New Products and Reimbursement as Growth Catalysts

The full clinical launch of RaDaR ST, which can detect disease at extremely low levels, and MolDX reimbursement for PanTracer Liquid provide important new revenue levers. Management expects PanTracer liquid biopsy to contribute mid‑single‑digit millions in revenue, helping diversify growth beyond the legacy testing base.

Encouraging Early Adoption of RaDaR ST

Roughly 29% of prior RaDaR 1.0 customers have already ordered the new RaDaR ST test, pointing to a promising upgrade cycle. About 34% of RaDaR ST orders included additional NeoGenomics tests, and all RaDaR ST results were delivered faster than published turnaround times, supporting cross‑sell potential and customer satisfaction.

Raised 2026 Revenue Outlook and Growth Cadence

The company nudged its 2026 revenue guidance higher to $797–803 million from $793–801 million, reinforcing confidence in the growth trajectory. Management now expects year‑over‑year revenue growth of about 9% in Q2, 9–10% in Q3, and more than 10% in Q4, suggesting an accelerating top‑line profile into 2026.

Improving Cash Flow and Solid Liquidity Position

Cash used in operations improved sharply to $8.1 million in Q1 from about $25.3 million a year earlier, reflecting better working capital and growing profitability. NeoGenomics ended the quarter with $146 million in cash, and management expects to be free‑cash‑flow positive for the full year, a key milestone for investors focused on sustainability.

Stepped-Up Commercial and Operational Investments

To support RaDaR ST and PanTracer uptake, NeoGenomics plans to add roughly 25 sales resources by the third quarter, signaling a push to accelerate adoption. The Pathline acquisition has strengthened the company’s presence in the Northeast, which is now growing at 1.5 times the national average, while about 330 interfaces, including Epic Aura, are being leveraged to drive ordering and utilization.

Pipeline and R&D Build Long-Term Optionality

Management highlighted targeted R&D investment in whole genome sequencing and a next‑generation minimal residual disease platform, with data expected next year and a potential launch as early as 2028. The company is also broadening its nonclinical menu with offerings such as an AML flow panel and new IHC markers, aiming to deepen relationships with pharma and research partners over time.

Nonclinical Revenue Remains a Drag

Nonclinical revenue fell 15% year over year to $15.5 million, primarily due to expected softness in pharma services, even as ODS posted double‑digit growth. Management now anticipates nonclinical revenue will be down low‑ to mid‑single digits for 2026, meaning this segment is likely to remain a modest headwind against otherwise strong clinical momentum.

Q1 Gross Margin Hurt by Acquisition and Launch Timing

Adjusted gross margin came in at 46%, down about 80 basis points year over year, as temporary factors weighed on profitability. The Pathline acquisition and the decision to launch PanTracer Liquid ahead of MolDX approval contributed roughly 150 basis points of headwind, compounded by higher freight and fuel costs tied to geopolitical pressures.

Payer and Reimbursement Timing Adds Near-Term Uncertainty

While the reimbursement win for PanTracer Liquid is a major step, management cautioned that broader commercial coverage for liquid biopsy and RaDaR ST will take time to build. With Medicare playing a significant role in the mix, the pace and breadth of commercial payer adoption will determine how quickly NeoGenomics can fully monetize these advanced assays.

Contract Rationalization and Weather Create Short-Term Noise

NeoGenomics deliberately exited a high‑volume, low‑value contract that represented about 3–4% of volumes, which pressured near‑term metrics but should improve economics over time. Severe weather, particularly in the Northeast, also weighed on Q1 volumes, adding a transitory headwind that management expects to fade in coming quarters.

Pathline Integration Weighs on Margins but Adds Scale

The Pathline deal is delivering strategic benefits in a key region, but it currently dilutes gross margin and complicates volume attribution due to load‑balancing across the lab network. Over time, the company expects integration synergies and network optimization to mitigate the dilution and support stronger profitability in the combined footprint.

Convertible Debt Refinancing on the Horizon

NeoGenomics flagged a roughly $342 million convertible coming due in January 2028, noting that refinancing will be necessary and is expected to be addressed in the second half of 2026. While this introduces capital markets execution risk, management is already engaging with banks, and improving cash flow should strengthen the balance sheet ahead of that event.

Execution Risk Around NGS Adoption and Platforms

A meaningful portion of the upgraded outlook hinges on sustaining high NGS growth, with guidance assuming about 22% NGS growth excluding liquid biopsy for the year. Any slowdown in adoption, delays in Epic Aura rollouts, or slower‑than‑expected commercial traction for PanTracer could pressure results, making execution in these areas a key watch item for shareholders.

Guidance Points to Sustained Growth and Margin Expansion

NeoGenomics raised its 2026 revenue range to $797–803 million and reiterated adjusted EBITDA guidance of $55–57 million, implying strong double‑digit profit growth. Underpinning this view are mid‑single‑digit‑million contributions from RaDaR ST and PanTracer, modest declines in nonclinical revenue, expected roughly 100 basis points of gross margin expansion for the year, and a revenue cadence that strengthens as 2026 approaches.

NeoGenomics’ earnings call painted the picture of a diagnostics company leaning into high‑growth NGS assets while carefully managing costs and balance sheet risks. For investors, the story is increasingly about execution: if the company can sustain NGS momentum, ramp new products, and navigate reimbursement and refinancing hurdles, the current positive trajectory appears well supported.